Vurghun Ahmadov's Colleagues at REGENXBIO Inc.
Gary N.Y. Chan
Research Scientist II, Preclinical Development, Pharmacokinetics
Vurghun Ahmadov's Contact Details
(240) 552-8181
Gaithersburg, Maryland, United States
REGENXBIO Inc.
Vurghun Ahmadov's Company Details
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO’s AAV Therapeutic platform, including Novartis’ ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people.